Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 5, Number 6, December 2015, pages 333-336


Observational Study of the Use of Insulin Glargine as Basal Therapy in Patients With Type 2 Diabetes Mellitus in Morocco

Tables

Table 1. Characteristics of the Study Population at Inclusion (Baseline)
 
Characteristic
All values shown are n (%), or mean ± SD.
Sex
  Male/female220/274 (44.5/55.5)
Age (years)57.5 ± 10.3
Age group (years)
  18 - 4015 (3.1)
  41 - 5098 (20.0)
  51 - 60185 (37.7)
  61 - 70133 (27.1)
  > 7060 (12.2)
Duration of diabetes (years)9.8 ± 6.1
Body mass index
  < 25 kg/m2118 (25.3)
  25 - 30 kg/m2230 (49.1)
  > 30 kg/m2120 (25.6)
Insulin therapy
  Initiation of insulin glargine388 (78.1)
  Modification of insulin (change to insulin glargine)109 (21.9)

 

Table 2. Changes in Antidiabetic Treatments Over the 6-Month Study Period
 
Week 12 (visit 2)Week 26 (visit 3)
Results are shown as n (%). OAD: antidiabetic drugs.
Total number of OAD changes150/477 (31.4)57/454 (12.6)
  OAD stopped98/477 (20.5)37/454 (8.1)
  OAD added87/477 (18.2)31/442 (7.0)
Sulphonylureas stopped48/477 (10.1)16/454 (3.5)
Biguanides stopped28/477 (5.9)16/454 (3.5)
Insulin glargine
  Dose changed398/484 (82.2)225/470 (47.9)
  Rapid insulin added45/484 (9.3)33/470 (7.0)

 

Table 3. Evolution of Efficacy Outcome Measures During the 6-Month Study Period
 
InclusionWeek 12Week 26P
I-W12I-W26
Values shown are n (%), or mean ± SD. FBG: fasting blood glucose.
HbA1c ≤ 7%0 (0)55 (11.5)149 (32.0)
HbA1c (%)9.37±1.148.08±1.037.43±0.87< 0.001< 0.001
FBG (mg/dL)237.5 ± 66.9154.4 ± 47.7129.5 ± 35.1< 0.001< 0.001